Physician profile
Irwin Goldstein
NPI 1366528127
$30,636.61
in general payments reported to CMS, 2019-2025
15 companies · $73.94 in 2025
The $73.94 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $30K · 2020: $141 · 2021: $38.99 · 2022: $108 · 2023: $109 · 2024: $97.54 · 2025: $73.94.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $242 · Education: $38.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $242.39 |
| Education | $38.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amag Pharmaceuticals, INC. | $29,912.67 | 2019-2020 | |
| Amgen INC. | $149.89 | 2019 | |
| Pfizer INC. | $124.66 | 2020-2025 | |
| Hologic Sales and Service, LLC | $94.50 | 2020-2023 | Coolseal Generator |
| Dysis Medical, INC. | $60.98 | 2022 | |
| Mayne Pharma Commercial LLC | $60.90 | 2024-2025 | |
| Abbvie INC. | $52.46 | 2020-2021 | |
| Astellas Pharma Global Development | $46.58 | 2024 | Veozah |
| Aspira Women'S Health INC | $39.52 | 2022 | |
| Coopersurgical, INC. | $21.76 | 2023 | Paragard T 380a |
| Scilex Pharmaceuticals INC. | $20.91 | 2023 | Elyxyb |
| Astellas Pharma US INC | $15.78 | 2019 | |
| Exeltis, USA INC. | $14.56 | 2024 | Slynd |
| Endo Pharmaceuticals INC. | $14.28 | 2019 | |
| Organon LLC | $7.16 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Irwin Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.